Literature DB >> 8500984

Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide.

J C Brooks-Kaiser1, L A Bourque, D W Hoskin.   

Abstract

Administration of high dose cyclophosphamide (CY, 200 mg/kg body weight) to adult mice induces transient, nonspecific suppressor activity in the spleen of treated animals. Characterization of the CY-induced natural suppressor (NS) cells which inhibit mixed lymphocyte reactions revealed a heterogeneous population of lymphocytes expressing the CD8 T cell marker and the B220 B cell marker, as well as cells bearing the granulocyte-monocyte marker CD11b. On a cell per cell basis the most potent of these suppressors were found to be positive for CD11b. Inhibitory activity was also detected in the CD8-, CD11b-, B220- compartment of CY-spleen, suggesting the presence of null NS cells. The fact that several phenotypically distinct cell populations contribute to the overall inhibitory effect of CY-spleen cells indicates that natural suppression defines an activity rather than a specific cell type. Interestingly, NS activity was observed to reside solely within the fraction of CY-spleen that is agglutinable with soybean agglutinin or wheat germ agglutinin, suggesting that expression of receptors for these plant lectins is a universal characteristic of CY-induced NS cells, regardless of their lineage. CY-spleen cell-mediated suppression of lymphoproliferative responses was found to be partially dependent on DNA synthesis and totally dependent on protein synthesis, but did not require cell-cell contact, indicating the production of soluble suppressor factor(s).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500984     DOI: 10.1016/0162-3109(93)90015-i

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  7 in total

1.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

3.  Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.

Authors:  Zhi-Chun Ding; Xiaoyun Lu; Miao Yu; Henrique Lemos; Lei Huang; Phillip Chandler; Kebin Liu; Matthew Walters; Antoni Krasinski; Matthias Mack; Bruce R Blazar; Andrew L Mellor; David H Munn; Gang Zhou
Journal:  Cancer Res       Date:  2014-04-29       Impact factor: 12.701

Review 4.  Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

Authors:  Michal Kuczma; Zhi-Chun Ding; Gang Zhou
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 5.  History of myeloid-derived suppressor cells.

Authors:  James E Talmadge; Dmitry I Gabrilovich
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 6.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

7.  Purification of melibiose-binding lectins from two cultivars of Chinese black soybeans.

Authors:  Peng Lin; Xiujuan Ye; Tb Ng
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2008-12       Impact factor: 3.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.